{"classes":[{"categories":[{"measurements":[{"comment":"NA = not estimable, could not be calculated due to too few events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"11.5"},{"comment":"NA = not estimable, could not be calculated due to too few events.","groupId":"OG001","lowerLimit":"2.3","upperLimit":"NA","value":"4.9"},{"comment":"NA = not estimable, could not be calculated due to too few events.","groupId":"OG002","lowerLimit":"1.9","upperLimit":"NA","value":"15.2"},{"comment":"NA = not estimable, could not be calculated due to too few events.","groupId":"OG003","lowerLimit":"1.9","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"DOR was applicable to participants who achieved at least a PR, and was measured from the first observation of PR or better to the time of disease progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses, in 28-day cycles, to identify the dose level with acceptable safety.","id":"OG000","title":"Safety Run-In: Cobimetinib + Venetoclax"},{"description":"Participants received cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses and atezolizumab (on Day 1 and Day 15) at a fixed dose of 840 mg IV, in 28-day cycles, to identify the dose level with acceptable safety.","id":"OG001","title":"Safety Run-In: Cobimetinib + Venetoclax + Atezolizumab"},{"description":"Participants received cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase. Treatment continued until disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurred first.","id":"OG002","title":"B: Cobimetinib + Venetoclax"},{"description":"Participants received cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase plus atezolizumab IV infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment continued until disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurred first.","id":"OG003","title":"C: Cobimetinib + Venetoclax + Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"The safety evaluable population included all participants who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"Time from the first observation of partial response (PR) or better to the time of disease progression (up to approximately 3 years, 7 months)","title":"Duration of Response (DOR) as Determined by the Investigator Using IMWG Response Criteria","type":"SECONDARY","unitOfMeasure":"Months"}